cir-ITCH was shown to prevent gastric cancer tumourgenesis through the Wnt/beta-catenin signalling pathway by sequestering miR-17.
Cir-ITCH inhibits gastric cancer migration, invasion and proliferation by regulating the Wnt/beta-catenin pathway.